according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Loratadine / Montelukast Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 H361f: Suspected of damaging fertility.

Long-term (chronic) aquatic hazard, Cat- H411: Toxic to aquatic life with long lasting effects.

egory 2

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H361f Suspected of damaging fertility.

H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use. P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Loratadine

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form combustible dust concentrations in air during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No.	Classification	Concentration
	EC-No.		(% w/w)
	Index-No.		(,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	Registration number		
Montelukast	151767-02-1	Eye Irrit. 2; H319	>= 1 - < 10
Loratadine	79794-75-5	Repr. 2; H361f	>= 3 - < 10
		Aquatic Acute 1;	
		H400	
		Aquatic Chronic 1;	
		H410	
		M-Factor (Acute	
		aquatic toxicity): 1	
		M-Factor (Chronic	
		aquatic toxicity): 1	

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 1.4 09.04.2021 4579035-00005 Date of first issue: 08.07.2019

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging fertility.

Contact with dust can cause mechanical irritation or drying of

the skin.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

 Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Date of last issue: 10.10.2020 Version Revision Date: SDS Number: 1.4 09.04.2021 4579035-00005 Date of first issue: 08.07.2019

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation Advice on safe handling Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

If exposure to chemical is likely during typical use, provide eye Hygiene measures

> flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
		of exposure)		

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Montelukast	151767-02- 1	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal
Loratadine	79794-75-5	TWA	40 μg/m3 (OEB 3)	Internal
		Wipe limit	400 μg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Equipment should conform to NS EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : tablet

Colour : No data available
Odour : No data available
Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form combustible dust concentrations in air during pro-

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Version **Revision Date:** SDS Number: Date of last issue: 10.10.2020 Date of first issue: 08.07.2019 1.4 09.04.2021 4579035-00005

cessing, handling or other means.

Flammability (liquids) Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Flash point Not applicable

Auto-ignition temperature No data available

Decomposition temperature

Decomposition tempera-

No data available ture

pΗ

No data available

Viscosity

Viscosity, kinematic Not applicable

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure Not applicable

Relative density No data available

Density No data available

Relative vapour density Not applicable

Particle characteristics

Particle size No data available

9.2 Other information

Explosives Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Evaporation rate Not applicable

Molecular weight No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form combustible dust concentrations in air during pro-

cessing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of:

exposure

Inhalation
Skin contact
Ingestion

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Montelukast:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 5.000 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Loratadine:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,05 mg/l

Exposure time: 1 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Components:

Montelukast:

Species : Rabbit

Result : Mild skin irritation

Loratadine:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Montelukast:

Species : Rabbit

Result : Severe irritation

Loratadine:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Montelukast:

Remarks : No data available

Loratadine:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Montelukast:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster fibroblasts

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: negative

Test Type: Alkaline elution assay Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Loratadine:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Cell type: Bone marrow Application Route: Oral

Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:

Montelukast:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Result : negative

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Result : negative

Loratadine:

Species : Rat
Application Route : Oral
Exposure time : 2 Years

LOAEL : 10 mg/kg body weight

Result : positive

Species : Monkey
Application Route : Oral
Exposure time : 17 Months

NOAEL : 40 mg/kg body weight

Result : negative

Reproductive toxicity

Suspected of damaging fertility.

Components:

Montelukast:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 800 mg/kg body weight

Result: Animal testing did not show any effects on fertility.

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: LOAEL: 200 mg/kg body weight

Symptoms: Reduced fertility

Test Type: Fertility Species: Rat, female Application Route: Oral

Fertility: NOAEL: 100 mg/kg body weight

Symptoms: Reduced fertility

Loratadine:

Effects on fertility : Species: Rat, male

Application Route: Oral

Fertility: LOAEL: 64 mg/kg body weight

Result: Effects on fertility

Effects on foetal develop-

ment

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 48 mg/kg body weight

Result: Embryo-foetal toxicity

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Version Revision Date: SDS Number: Date of last issue: 10.10.2020 1.4 09.04.2021 4579035-00005 Date of first issue: 08.07.2019

Species: Rabbit

Application Route: Oral

Developmental Toxicity: LOAEL: 48 mg/kg body weight

Result: Embryo-foetal toxicity

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 12 mg/kg body weight

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Montelukast:

Species : Monkey, male and female

NOAEL : 150 - 300 mg/kg

Application Route : Oral Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Rat
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Remarks : No significant adverse effects were reported

Species : Mouse
NOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Loratadine:

Species : Rat

NOAEL : 4 mg/kg

LOAEL : 8 mg/kg

Application Route : Oral

Exposure time : 180 Days

Target Organs : Central nervous system

Remarks : Effects are of limited toxicological significance.

Species : Monkey NOAEL : 0,4 mg/kg

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

LOAEL : 4 mg/kg
Application Route : Oral
Exposure time : 180 Days

Target Organs : Central nervous system

Remarks : Effects are of limited toxicological significance.

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Montelukast:

Skin contact : Remarks: May irritate skin. Eve contact : Symptoms: Severe irritation

Ingestion : Symptoms: upper respiratory tract infection, pharyngitis,

Headache, Cough, Abdominal pain, Diarrhoea, Fever

Loratadine:

Ingestion : Symptoms: Fatigue, Headache, dry mouth, Nausea

SECTION 12: Ecological information

12.1 Toxicity

Components:

Montelukast:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 0,0778 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 0,0675 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

Remarks: No toxicity at the limit of solubility

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mq/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 100 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,073 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

NOEC: 0,0816 mg/l Exposure time: 7 d

Species: Cyprinodon variegatus (sheepshead minnow)

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,23 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

Remarks: No toxicity at the limit of solubility

Loratadine:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 0,382 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0,83 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 0,95

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0,053

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox- :

icity)

1

Toxicity to microorganisms : EC50 : > 1.000 mg/l

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Version Revision Date: Date of last issue: 10.10.2020 SDS Number: Date of first issue: 08.07.2019 1.4 09.04.2021 4579035-00005

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0,084 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0,078 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1

12.2 Persistence and degradability

Components:

Montelukast:

Biodegradability Result: not rapidly degradable

> Biodegradation: 0 % Exposure time: 28 d

Stability in water Hydrolysis: 50 %(21,7 h)

Loratadine:

Result: not rapidly degradable Biodegradability

Biodegradation: 50 % Exposure time: 20 d

Method: OECD Test Guideline 314

Degradation half life (DT50): 283 d Stability in water

12.3 Bioaccumulative potential

Components:

Montelukast:

Partition coefficient: n-

log Pow: > 4,3

octanol/water Loratadine:

Partition coefficient: n-

log Pow: 2,35

octanol/water

12.4 Mobility in soil

Components:

Loratadine:

Distribution among environ-

mental compartments

log Koc: 5,25

Method: OECD Test Guideline 106

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Other adverse effects

Product:

Endocrine disrupting poten-

tial

The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

N.O.S.

(Loratadine)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S. (Loratadine)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Loratadine)

14.3 Transport hazard class(es)

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen- : 956

ger aircraft)

Packing instruction (LQ) : Y956
Packing group : III

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

Date of last issue: 10.10.2020 Version Revision Date: SDS Number: 1.4 09.04.2021 4579035-00005 Date of first issue: 08.07.2019

Labels Miscellaneous

14.5 Environmental hazards

Environmentally hazardous yes

Environmentally hazardous yes

Environmentally hazardous yes

IMDG

Marine pollutant yes

IATA (Passenger)

Environmentally hazardous yes

IATA (Cargo)

Environmentally hazardous yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

Not applicable

Not applicable

REACH - Restrictions on the manufacture, placing on

the market and use of certain dangerous substances.

preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

REACH - List of substances subject to authorisation Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de-Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu-Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia-Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 2 Quantity 1 E2

ENVIRONMENTAL 200 t 500 t

HAZARDS

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations,

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H319 : Causes serious eye irritation. H361f : Suspected of damaging fertility.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population: LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quanti-

according to Regulation (EC) No. 1907/2006



Loratadine / Montelukast Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 10.10.2020

 1.4
 09.04.2021
 4579035-00005
 Date of first issue: 08.07.2019

tative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Repr. 2 H361f Calculation method Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN